ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis signs deal with BeiGene to bolster immunotherapy pipeline
December 22, 2021Novartis has entered an option, partnership and licence agreement for BeiGene’s anti-cancer therapy, ociperlimab (BGB-A1217), bolstering its research and development works in immuno-oncology. -
Novartis Announces Agreement with BeiGene for TIGIT Inhibitor Ociperlimab
December 21, 2021Novartis announced the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company’s research and development activities in immuno-oncology.
Pharma Sources Insight January 2025
